Uridine5'-(pentahydrogentetraphosphate),P'5'-esterwith2'-deoxycytidine,sodiumsalt(1:4) 地纽福索四钠
CAS 318250-11-2 MFCD18250112
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
相关文献及参考
- [2]. Yerxa BR, et al. Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther. 2002 Sep;302(3):871-80.
- [3]. Farjo R, et al. Expression profiling after retinal detachment and reattachment: a possible role for aquaporin-0. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):511-21.
- [1]. Button B, et al. Mechanosensitive ATP release maintains proper mucus hydration of airways. Sci Signal. 2013 Jun 11;6(279):ra46.
- [1]. Button B, et al. Mechanosensitive ATP release maintains proper mucus hydration of airways. Sci Signal. 2013 Jun 11;6(279):ra46.
- [2]. Yerxa BR, et al. Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther. 2002 Sep;302(3):871-80.
- [3]. Fa